Beacon Therapeutics has secured a £55.6 million Series C financing to accelerate commercial preparations for its lead gene therapy, laru-zova.

The funding comes ahead of pivotal clinical data expected in the second half of 2026.

London-based Syncona invested £18.1m in the round, alongside a syndicate led by Goldman Sachs Alternatives, with participation from new and existing life sciences investors.

The funding will support the completion of laru-zova’s development for X-linked retinitis pigmentosa, as well as advance the Flordian firm’s wider ophthalmology pipeline.

Following the raise, listed Syncona’s holding in Beacon has been written up by £29.3m, with its ownership expected to reach 38.4% once the full Series C financing is drawn down.